Wall Street brokerages expect that Lantheus Holdings Inc (NASDAQ:LNTH) will report $0.21 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Lantheus’ earnings. The lowest EPS estimate is $0.13 and the highest is $0.29. Lantheus reported earnings of $0.42 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 50%. The business is scheduled to report its next earnings results on Tuesday, August 7th.
According to Zacks, analysts expect that Lantheus will report full-year earnings of $0.86 per share for the current fiscal year, with EPS estimates ranging from $0.69 to $1.02. For the next financial year, analysts forecast that the company will report earnings of $1.21 per share, with EPS estimates ranging from $1.19 to $1.23. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Lantheus.
Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.22 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.22. Lantheus had a negative return on equity of 145.14% and a net margin of 38.32%. The firm had revenue of $82.63 million for the quarter, compared to analyst estimates of $81.15 million. During the same period in the previous year, the firm earned $0.11 earnings per share. The company’s revenue was up 1.6% compared to the same quarter last year.
In other news, Director Julie Mchugh sold 4,560 shares of the business’s stock in a transaction that occurred on Monday, June 25th. The stock was sold at an average price of $14.72, for a total transaction of $67,123.20. Following the completion of the sale, the director now owns 14,752 shares in the company, valued at $217,149.44. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Cesare Orlandi sold 8,801 shares of the business’s stock in a transaction that occurred on Monday, April 30th. The shares were sold at an average price of $18.00, for a total value of $158,418.00. Following the sale, the insider now owns 97,216 shares of the company’s stock, valued at approximately $1,749,888. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,555 shares of company stock valued at $301,033. Corporate insiders own 1.20% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas bought a new stake in Lantheus during the fourth quarter worth $200,000. AMP Capital Investors Ltd bought a new stake in Lantheus during the fourth quarter worth $205,000. MetLife Investment Advisors LLC bought a new stake in Lantheus during the fourth quarter worth $267,000. Allianz Asset Management GmbH bought a new stake in Lantheus during the fourth quarter worth $431,000. Finally, American International Group Inc. grew its holdings in Lantheus by 14.7% during the fourth quarter. American International Group Inc. now owns 24,147 shares of the medical equipment provider’s stock worth $494,000 after buying an additional 3,101 shares in the last quarter. Institutional investors and hedge funds own 92.02% of the company’s stock.
Lantheus traded down $0.10, hitting $15.10, during trading on Wednesday, according to Marketbeat.com. The company’s stock had a trading volume of 343,700 shares, compared to its average volume of 392,664. Lantheus has a twelve month low of $13.55 and a twelve month high of $24.45. The company has a debt-to-equity ratio of 7.87, a quick ratio of 2.80 and a current ratio of 3.51. The firm has a market cap of $585.69 million, a PE ratio of 15.30, a price-to-earnings-growth ratio of 1.49 and a beta of 1.37.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.